Clinical Trial Update: TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating TPF plus radiotherapy and cetuximab to avoid total laryngectomy in larynx cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Laryngeal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• Cetuximab (cetuximab)
• DOCETAXEL (DOCETAXEL)
• Radiotherapy

Snippet

Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED